Related Experiment Video
Updated: May 25, 2026

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
Published on: April 3, 2018
Targeting HMGB1 inhibits ovarian cancer growth and metastasis by lentivirus-mediated RNA interference
Jie Chen1, Xiaoyan Liu, Jie Zhang
1Department of Maternal and Child Health Care, School of Public Health, Shandong University, Jinan, China.
Abstract:
High-mobility group box 1 (HMGB1), a nuclear and extracellular protein, is implicated in the development and progression of some types of cancers. However, no information is available to date regarding the function of HMGB1 in ovarian cancer. In this study, we performed cDNA microarray analysis and identified HMGB1 as a gene dramatically elevated in the highly invasive subclone S1 compared with the low invasive subclone S21 derived from the same cell line SKOV3. Then lentivirus vector with HMGB1 shRNA was constructed and infected the highly invasive cell line S1, A1, and HO8910PM. Real-time RT-PCR, Western blot, and IHC results confirmed the down-regulation of HMGB1 expression by its shRNA was about 80-90% at both the mRNA and protein levels. Knockdown of HMGB1 significantly suppressed ovarian cancer cell proliferation and induced cell cycle arrest at the G1/G0 phase, which was accompanied by decreased expressions of cyclin D1 and PCNA. Furthermore, knockdown of HMGB1 induced ovarian cancer cell apoptosis, which was mediated by increased expression of Bax and decreased expression of Bcl-2. Finally, knockdown of HMGB1 significantly inhibited ovarian cancer cell invasion and metastasis, which was regulated by decreased expressions of MMP2 and MMP9. Serum HMGB1 levels in patients with epithelial ovarian cancer were significantly higher than that in patients with benign ovarian tumor and healthy controls. These results indicate that HMGB1 is a newly identified gene associated with ovarian cancer growth and metastasis. HMGB1 may serve as a new therapeutic target for the treatment of ovarian cancer in the future.
Insights
High-mobility group box 1 (HMGB1) is elevated in ovarian cancer, driving proliferation, invasion, and metastasis. Targeting HMGB1 may offer a new therapeutic strategy for epithelial ovarian cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- High-mobility group box 1 (HMGB1) is a protein involved in cancer development.
- The role of HMGB1 in ovarian cancer remains largely uncharacterized.
Purpose of the Study:
- To investigate the function of HMGB1 in ovarian cancer progression.
- To explore HMGB1 as a potential therapeutic target for ovarian cancer.
Main Methods:
- cDNA microarray analysis to identify HMGB1 expression.
- Lentivirus-mediated shRNA to knockdown HMGB1 in ovarian cancer cell lines.
- Real-time RT-PCR, Western blot, and IHC to confirm knockdown efficacy.
- Assays for cell proliferation, cell cycle, apoptosis, invasion, and metastasis.
Main Results:
- HMGB1 expression was significantly elevated in highly invasive ovarian cancer cells.
- HMGB1 knockdown suppressed proliferation, induced G1/G0 cell cycle arrest, and promoted apoptosis.
- HMGB1 knockdown inhibited invasion and metastasis by downregulating MMP2 and MMP9.
- Elevated serum HMGB1 levels were observed in epithelial ovarian cancer patients.
Conclusions:
- HMGB1 is a key driver of ovarian cancer growth, invasion, and metastasis.
- HMGB1 plays a significant role in ovarian cancer pathogenesis.
- HMGB1 represents a promising therapeutic target for ovarian cancer treatment.
Related Concept Videos
Experimental RNAi
MicroRNAs
MicroRNAs
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
